Postmarketing Observational Study to Evaluate the Work Productivity, Safety and Efficacy of HUMIRA (Adalimumab sc) for the Treatment of Moderate to Severe Plaque Psoriasis in Daily Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Acronyms LOTOS
- Sponsors Abbott Laboratories; AbbVie
- 30 Jan 2017 Planned End Date changed from 1 Oct 2020 to 1 Jan 2021.
- 30 Jan 2017 Planned primary completion date changed from 1 Oct 2020 to 1 Jan 2021.
- 01 Aug 2016 Planned number of patients changed from 5500 to 3000.